GEN-MKT-18-7897-A
Mar 17, 2022 | Blogs, Cannabis, Food / Beverage, Food and Beverage, Forensic | 0 comments
Read time: 2 minutes
We’ve all heard about the doping scandal that shocked the cycling world at the 1998 Tour de France, right? Well, because of that scandal, the International Olympic Committee (IOC) arranged a World Conference on Doping that brought together all parties involved in the fight against doping. The Lausanne Declaration on Doping in Sport1 was adopted by the conference in February 1999 and included a call for an international anti-doping agency to be operational for the 2000 Olympics in Sydney. The World Anti-Doping Agency (WADA)2 was established in November 1999 to answer that call.
WADA is composed and funded equally by sports organizations and governments across the world, and its key activities include scientific research, education, development of anti-doping capacities and monitoring of the World Anti-Doping Code,3 which is a standardized set of rules for all sports and countries. WADA was set up as a foundation under the initiative of the IOC with the support and participation of intergovernmental organizations, governments, public authorities and other public and private bodies that fight doping in sports.
When it comes to cannabis, marijuana is still banned globally in most professional sports and in the Olympics.4,5 Based on this ban, US sprinter Sha’Carri Richardson was suspended from the 2021 Olympics in Tokyo after testing positive for marijuana.6 Let’s take a look at how cases like this affect the global legalization of cannabis and the decisions made by WADA.
Richardson suspension amidst global cannabis legalization
After testing positive for a chemical found in marijuana, Richardson was banned from competing in the 2021 Olympics.6 But how much longer will marijuana be considered a performance-enhancing drug, and might WADA remove it from its list of banned substances?
Times are changing as countries move toward some form of marijuana legalization and cannabis imports and exports on a global scale. The notion that marijuana is as harmful as narcotics and has the potential to improve physical capabilities might be antiquated, and scientific studies are ongoing to assess this notion.
Many global authorities are conducting extensive regulatory reviews of marijuana for medical and nonmedical access. Cannabis has the potential to impact the health of athletes as well as their performance in both training and in competition. Scientific research on these potential effects aims to identify the challenges related to elite athletic performance, and pinpoint important research areas that still need to be addressed.
Research findings indicate that while cannabis is more prevalent in some athletes, there is no direct evidence of performance-enhancing effects in those athletes.7 So, could we see cannabis removed from the banned substance list across global sports?
The future of cannabis legalization in sport
The suspension of Richardson from the 2021 Olympics resulted in widespread confusion over why marijuana is considered a performance-enhancing drug. In response to this confusion and several requests submitted by stakeholders, WADA is due to review its cannabis ban. However, WADA has reiterated that cannabis will remain forbidden for the 2022 athletic season.7
Only time will tell whether the mass outrage at Richardson’s suspension prompted WADA to go through the motions of reviewing its marijuana ban to appease public opinion or whether revisiting the ban reflects a shift in thinking about marijuana as a performance-enhancing drug. If delta-9 THC from marijuana isn’t banned, could the legal delta-8 be the new psychoactive product of choice for athletes? Or even delta-10? Does WADA even differentiate between those two isomers? We’ll keep an eye on these and other developments in the cannabis world.
Leave a comment and let us know your thoughts. Are you for or against removing cannabis from the banned substance list, and do you think it’ll happen?
References
Ware M. A. et al. Cannabis and the Health and Performance of the Elite Athlete. Clin J Sport Med. 2018, 28(5), 480–484. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116792/
RUO -MKT-18- 14118-A
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
Posted by
You must be logged in to post a comment.
Share this post with your network